MedTrace Logo

Ivermectin Role in Covid-19 Clinical Trial

NCT04746365 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2021-02-09

No results posted yet for this study

Summary

Because ivermectin is being used to treat COVID-19 with insufficient evidence, the investigator conducted a randomized clinical trial to investigate the efficacy and safety of ivermectin in comparison to hydroxychloroquine and placebo in severe COVID-19 patients. The study was conducted in Shebin-Elkom teaching hospital and recruited patients from December 6, 2020, to January 31, 2021.

Conditions

  • Covid19

Interventions

DRUG

ivermectin

ivermectin is anthelmintic

DRUG

hydroxychloroquine

hydroxychloroquine is antimalarial.

DRUG

Placebo

Standard treatments

Sponsors & Collaborators

  • Shebin El-Kom Teaching Hospital

    collaborator OTHER

  • Elaraby Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-06
Primary Completion
2021-01-31
Completion
2021-02-06

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746365 on ClinicalTrials.gov